Are antibodies directed against amyloid-β (Aβ) oligomers the last call for the Aβ hypothesis of Alzheimer's disease?

Author:

Panza Francesco123,Lozupone Madia1,Dibello Vittorio4,Greco Antonio3,Daniele Antonio56,Seripa Davide3,Logroscino Giancarlo12,Imbimbo Bruno P7

Affiliation:

1. Neurodegenerative Disease Unit, Department of Basic Medicine, Neuroscience, & Sense Organs, University of Bari Aldo Moro, Bari, Italy

2. Department of ClinicalResearch in Neurology, Center for Neurodegenerative Diseases and the AgingBrain, University of Bari “Aldo Moro”, “Pia Fondazione Cardinale G. Panico”, Tricase, Lecce, Italy

3. Geriatric Unit, Fondazione IRCCS “Casa Sollievo della Sofferenza”, SanGiovanni Rotondo, Foggia, Italy

4. Interdisciplinary Department of Medicine (DIM), Section of Dentistry, University of Bari Aldo Moro, Bari, Italy

5. Institute of Neurology, Catholic University of Sacred Heart, Rome, Italy

6. Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy

7. Department of Researchand Development, Chiesi Farmaceutici, Parma, Italy

Publisher

Future Medicine Ltd

Subject

Oncology,Immunology,Immunology and Allergy

Reference14 articles.

1. Malone E. Lilly/AstraZeneca's lanabecestat becomes latest BACE inhibitor casualty. Scrip, June 12 (2018).

2. Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer’s Disease

3. Barber J. Merck & Co. Terminates Phase III study of verubecestat in prodromal Alzheimer's disease. FirstWorld Pharma, February 13 (2018).

4. Emerging drugs to reduce abnormal β-amyloid protein in Alzheimer’s disease patients

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3